
Citius Pharmaceuticals Investor Relations Material
Latest events

Investor Update
Citius Pharmaceuticals

Q3 2025
12 Aug, 2025

Q2 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Citius Pharmaceuticals Inc
Access all reports
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products. The company's pipeline includes a range of therapeutic candidates targeting various medical needs. Key products include Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections, and LYMPHIR, a targeted immunotherapy recently approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). Another notable product is CITI-002 (Halo-Lido), a topical formulation aimed at providing relief for hemorrhoids. The company is based in Cranford, New Jersey, and its shares are traded on the Nasdaq.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
CTXR
Country
🇺🇸 United States